Get the Stockscreener App
4.67
3.51%
-0.17
Galecto Inc stock is traded at $4.67, with a volume of 7,028.
It is down -3.51% in the last 24 hours and down -18.92% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$4.84
Open:
$4.69
24h Volume:
7,028
Relative Volume:
0.38
Market Cap:
$6.37M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-3.2207
EPS:
-1.45
Net Cash Flow:
$-36.91M
1W Performance:
-2.32%
1M Performance:
-18.92%
6M Performance:
-68.62%
1Y Performance:
-73.31%
1-Day Range:
$4.56
$4.69
1-Week Range:
$4.3932
$5.00
52-Week Range:
$4.24
$23.50
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
4.56 | 6.37M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.61 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.62 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.35 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.00 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.98 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Eterna Therapeutics (NASDAQ:ERNA) & Galecto (NASDAQ:GLTO) Head to Head Comparison - Defense World
Galecto stock hits 52-week low at $4.39 amid market challenges - MSN
Reviewing Eton Pharmaceuticals (NASDAQ:ETON) & Galecto (NASDAQ:GLTO) - Defense World
Galecto to Participate in Upcoming Investor Conferences - The Globe and Mail
Galecto stock hits 52-week low at $4.39 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partnrs Estimates Galecto FY2024 Earnings - Defense World
Brokers Set Expectations for Galecto FY2029 Earnings - Armenian Reporter
Galecto to Participate in Upcoming Investor Conferences -February 06, 2025 at 08:01 am EST - Marketscreener.com
Biotech Spotlight: Galecto Lines Up Triple Conference Showcase for Investors - StockTitan
Where are the Opportunities in (GLTO) - Stock Traders Daily
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Critical Analysis: Galecto (NASDAQ:GLTO) vs. ObsEva (NASDAQ:OBSV) - Defense World
(GLTO) On The My Stocks Page - Stock Traders Daily
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Galecto CEO Hans T. Schambye sells $7,509 in shares - Investing.com
Galecto (NASDAQ:GLTO) Shares Up 22.6% – Should You Buy? - Defense World
When (GLTO) Moves Investors should Listen - Stock Traders Daily
Galecto stock plunges to 52-week low at $4.78 amid market challenges - Investing.com Australia
Galecto stock hits 52-week low at $5.26 amid market challenges - Investing.com Nigeria
Galecto stock hits 52-week low at $5.26 amid market challenges By Investing.com - Investing.com South Africa
(GLTO) Trading Signals - Stock Traders Daily
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galecto Inc Stock (GLTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Firmani Lori | Interim CFO |
Jan 03 '25 |
Sale |
5.63 |
261 |
1,469 |
465 |
| Schambye Hans T. | Chief Executive Officer |
Jan 03 '25 |
Sale |
5.60 |
1,341 |
7,510 |
3,397 |
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):